344 related articles for article (PubMed ID: 18751930)
1. Medical treatment of primary sclerosing cholangitis: a role for novel bile acids and other (post-)transcriptional modulators?
Beuers U; Kullak-Ublick GA; Pusl T; Rauws ER; Rust C
Clin Rev Allergy Immunol; 2009 Feb; 36(1):52-61. PubMed ID: 18751930
[TBL] [Abstract][Full Text] [Related]
2. Novel Aspects in the Management of Cholestatic Liver Diseases.
Chazouillères O
Dig Dis; 2016; 34(4):340-6. PubMed ID: 27170387
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic role of bile acids and nuclear receptor agonists in fibrosing cholangiopathies.
Trauner M; Halilbasic E; Kazemi-Shirazi L; Kienbacher C; Staufer K; Traussnigg S; Hofer H
Dig Dis; 2014; 32(5):631-6. PubMed ID: 25034298
[TBL] [Abstract][Full Text] [Related]
4. Therapy of Primary Sclerosing Cholangitis--Today and Tomorrow.
Halilbasic E; Fuchs C; Hofer H; Paumgartner G; Trauner M
Dig Dis; 2015; 33 Suppl 2():149-63. PubMed ID: 26641242
[TBL] [Abstract][Full Text] [Related]
5. New therapies target the toxic consequences of cholestatic liver disease.
Jansen PLM
Expert Rev Gastroenterol Hepatol; 2018 Mar; 12(3):277-285. PubMed ID: 29310470
[TBL] [Abstract][Full Text] [Related]
6. Novel and emerging therapies for cholestatic liver diseases.
Goldstein J; Levy C
Liver Int; 2018 Sep; 38(9):1520-1535. PubMed ID: 29758112
[TBL] [Abstract][Full Text] [Related]
7. New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond.
Beuers U; Trauner M; Jansen P; Poupon R
J Hepatol; 2015 Apr; 62(1 Suppl):S25-37. PubMed ID: 25920087
[TBL] [Abstract][Full Text] [Related]
8. norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis.
Fickert P; Hirschfield GM; Denk G; Marschall HU; Altorjay I; Färkkilä M; Schramm C; Spengler U; Chapman R; Bergquist A; Schrumpf E; Nevens F; Trivedi P; Reiter FP; Tornai I; Halilbasic E; Greinwald R; Pröls M; Manns MP; Trauner M;
J Hepatol; 2017 Sep; 67(3):549-558. PubMed ID: 28529147
[TBL] [Abstract][Full Text] [Related]
9. Downregulation of TGR5 (GPBAR1) in biliary epithelial cells contributes to the pathogenesis of sclerosing cholangitis.
Reich M; Spomer L; Klindt C; Fuchs K; Stindt J; Deutschmann K; Höhne J; Liaskou E; Hov JR; Karlsen TH; Beuers U; Verheij J; Ferreira-Gonzalez S; Hirschfield G; Forbes SJ; Schramm C; Esposito I; Nierhoff D; Fickert P; Fuchs CD; Trauner M; García-Beccaria M; Gabernet G; Nahnsen S; Mallm JP; Vogel M; Schoonjans K; Lautwein T; Köhrer K; Häussinger D; Luedde T; Heikenwalder M; Keitel V
J Hepatol; 2021 Sep; 75(3):634-646. PubMed ID: 33872692
[TBL] [Abstract][Full Text] [Related]
10. Ursodeoxycholic acid and bile-acid mimetics as therapeutic agents for cholestatic liver diseases: an overview of their mechanisms of action.
Poupon R
Clin Res Hepatol Gastroenterol; 2012 Sep; 36 Suppl 1():S3-12. PubMed ID: 23141891
[TBL] [Abstract][Full Text] [Related]
11. Management of cholestatic disease in 2017.
de Vries E; Beuers U
Liver Int; 2017 Jan; 37 Suppl 1():123-129. PubMed ID: 28052628
[TBL] [Abstract][Full Text] [Related]
12. Nuclear receptors CAR and PXR; therapeutic targets for cholestatic liver disease.
Kakizaki S; Takizawa D; Tojima H; Horiguchi N; Yamazaki Y; Mori M
Front Biosci (Landmark Ed); 2011 Jun; 16(8):2988-3005. PubMed ID: 21622216
[TBL] [Abstract][Full Text] [Related]
13. The cholesterol-raising factor from coffee beans, cafestol, as an agonist ligand for the farnesoid and pregnane X receptors.
Ricketts ML; Boekschoten MV; Kreeft AJ; Hooiveld GJ; Moen CJ; Müller M; Frants RR; Kasanmoentalib S; Post SM; Princen HM; Porter JG; Katan MB; Hofker MH; Moore DD
Mol Endocrinol; 2007 Jul; 21(7):1603-16. PubMed ID: 17456796
[TBL] [Abstract][Full Text] [Related]
14. Nuclear receptors as drug targets in cholestatic liver diseases.
Halilbasic E; Baghdasaryan A; Trauner M
Clin Liver Dis; 2013 May; 17(2):161-89. PubMed ID: 23540496
[TBL] [Abstract][Full Text] [Related]
15. Multiple therapeutic targets in rare cholestatic liver diseases: Time to redefine treatment strategies.
Gerussi A; D'Amato D; Cristoferi L; O'Donnell SE; Carbone M; Invernizzi P
Ann Hepatol; 2020; 19(1):5-16. PubMed ID: 31771820
[TBL] [Abstract][Full Text] [Related]
16. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis.
Smith T; Befeler AS
Curr Gastroenterol Rep; 2007 Mar; 9(1):54-9. PubMed ID: 17335678
[TBL] [Abstract][Full Text] [Related]
17. Does ursodeoxycholic acid mediate immunomodulatory and anti-inflammatory effects in patients with primary sclerosing cholangitis?
van Milligen de Wit AW; Kuiper H; Camoglio L; van Bracht J; Jones EA; Tytgat GN; van Deventer SJ
Eur J Gastroenterol Hepatol; 1999 Feb; 11(2):129-36. PubMed ID: 10102223
[TBL] [Abstract][Full Text] [Related]
18. The evolution of farnesoid X, vitamin D, and pregnane X receptors: insights from the green-spotted pufferfish (Tetraodon nigriviridis) and other non-mammalian species.
Krasowski MD; Ai N; Hagey LR; Kollitz EM; Kullman SW; Reschly EJ; Ekins S
BMC Biochem; 2011 Feb; 12():5. PubMed ID: 21291553
[TBL] [Abstract][Full Text] [Related]
19. Effect of high-dose ursodeoxycholic acid on its biliary enrichment in primary sclerosing cholangitis.
Rost D; Rudolph G; Kloeters-Plachky P; Stiehl A
Hepatology; 2004 Sep; 40(3):693-8. PubMed ID: 15349909
[TBL] [Abstract][Full Text] [Related]
20. [Novel Insights of Primary Sclerosing Cholangitis and Primary Biliary Cholangitis].
Ahn DW
Korean J Gastroenterol; 2020 May; 75(5):246-256. PubMed ID: 32448856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]